Early signals suggest a potential link between the popular weight-loss drug Wegovy and a rare condition known as ischemic optic neuropathy (ION), often referred to as an “eye stroke.” However, medical experts emphasize that this risk remains extremely low and does not currently outweigh the proven benefits of the medication for weight management.
While the connection is not yet confirmed as causal, the findings have prompted regulatory bodies to advise patients to seek immediate medical attention if they experience sudden vision loss.
The Emerging Signal
The concern stems from a study published in March in the British Journal of Ophthalmology. Researchers analyzed side-effect reports submitted to the U.S. Food and Drug Administration (FDA) between December 2017 and December 2024.
Key findings from the data include:
* Total Reports: Out of 31,774 reports involving semaglutide-based drugs, only a small fraction involved eye issues.
* Wegovy vs. Ozempic: Among 3,070 reports for Wegovy, 28 noted ION. Among 20,608 reports for Ozempic (the same active ingredient used for diabetes), 47 noted ION.
* Proportional Risk: When adjusted for the time each drug has been on the market, the study authors concluded that the proportional risk of ION appeared higher with Wegovy than with Ozempic.
It is important to note that Rybelsus, another semaglutide drug approved for diabetes, showed no notable association with ION in this dataset.
Understanding Ischemic Optic Neuropathy
ION occurs when blood flow to the optic nerve is interrupted, causing damage that can lead to rapid, painless vision loss. It can affect one or both eyes.
“This is a very sudden and painless way to lose your eyesight,” explains Barbara Pierscionek, deputy dean of research and innovation at Anglia Ruskin University. “We’re not quite sure exactly how it happens, but it is essentially a blockage of the blood vessels in the eye.”
Despite the severity of the condition, it is rare. In the study, ION occurred in less than 1% of patients who reported any side effects while taking Wegovy.
Why Context Matters: Correlation vs. Causation
Experts caution against interpreting these findings as definitive proof that Wegovy causes eye strokes. The study relies on self-reported side effects, which are useful for detecting early warning signals but cannot establish causality or determine the true prevalence of the condition.
Several factors complicate the analysis:
- Unverified Data: The reports were not independently verified by medical experts and lack detailed patient histories.
- Pre-existing Risk Factors: Conditions such as high blood pressure, cardiovascular disease, and diabetes are known risk factors for ION. Since semaglutide is often prescribed to patients with metabolic issues, it is possible that these patients were already at higher baseline risk for ION, regardless of the drug.
- Dosage Differences: Wegovy typically contains a higher dose of semaglutide than Ozempic. While biologically plausible that a higher dose could increase risk, this remains unproven. As Dr. Brian Woods of the University of Galway notes, “At this stage, there is a significant likelihood that differences may be confounded by baseline risk and metabolic dynamics rather than dose alone.”
Expert Consensus and Recommendations
Despite the signal, the medical community maintains that the benefits of semaglutide continue to outweigh the risks. Dr. Amanda Adler, a professor at the University of Oxford, states that the overall rate of ION is so low that it does not justify halting treatment for those who benefit from it.
Regulatory bodies are taking a precautionary approach. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has advised semaglutide users to seek urgent medical care if they notice their eyesight getting worse quickly.
Conclusion
While early data highlights a potential association between Wegovy and rare eye strokes, the evidence is preliminary and the absolute risk remains minimal. Patients should remain vigilant for sudden vision changes but need not panic; continued monitoring and further research are required to fully understand the relationship between dosage, patient health profiles, and this rare side effect.
